[HTML][HTML] Artificially cloaked viral nanovaccine for cancer immunotherapy

M Fusciello, F Fontana, S Tähtinen, C Capasso… - Nature …, 2019 - nature.com
Virus-based cancer vaccines are nowadays considered an interesting approach in the field
of cancer immunotherapy, despite the observation that the majority of the immune responses …

Exploiting preexisting immunity to enhance oncolytic cancer immunotherapy

S Tähtinen, S Feola, C Capasso, N Laustio… - Cancer Research, 2020 - AACR
Because of the high coverage of international vaccination programs, most people worldwide
have been vaccinated against common pathogens, leading to acquired pathogen-specific …

[HTML][HTML] Personalized cancer vaccine platform for clinically relevant oncolytic enveloped viruses

E Ylösmäki, C Malorzo, C Capasso, O Honkasalo… - Molecular Therapy, 2018 - cell.com
The approval of the first oncolytic virus for the treatment of metastatic melanoma and the
compiling evidence that the use of oncolytic viruses can enhance cancer immunotherapies …

[HTML][HTML] Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

E Ylösmäki, L Ylösmäki, M Fusciello, B Martins… - Molecular Therapy …, 2021 - cell.com
Oncolytic viruses (OVs) have been shown to induce anti-cancer immunity and enhance
cancer immunotherapies, such as immune checkpoint inhibitor therapies. OV therapies can …

[HTML][HTML] Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin

E Ylösmäki, M Fusciello, B Martins, S Feola… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Intratumoral BCG therapy, one of the earliest immunotherapies, can lead to
infiltration of immune cells into a treated tumor. However, an increase in the number of BCG …

Identification of specific residues in avian influenza A virus NS1 that enhance viral replication and pathogenicity in mammalian systems

P Kanrai, A Mostafa, R Madhugiri… - Journal of General …, 2016 - microbiologyresearch.org
Reassortment of their segmented genomes allows influenza A viruses (IAV) to gain new
characteristics, which potentially enable them to cross the species barrier and infect new …

PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines

S Feola, J Chiaro, M Fusciello, S Russo, I Kleino… - International Journal of …, 2024 - Elsevier
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posed a
threat to public health and the global economy, necessitating the development of various …

[HTML][HTML] Reorganization of the host cell Crk (L)–PI3 kinase signaling complex by the influenza A virus NS1 protein

L Ylösmäki, C Schmotz, E Ylösmäki, K Saksela - Virology, 2015 - Elsevier
Abstract The non-structural protein-1 (NS1) of influenza A virus binds the p85β subunit of
phosphoinositide 3-kinase (PI3K) to induce PI3K activity in the infected cells. Some virus …

[HTML][HTML] Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy

L Ylösmäki, B Polini, S Carpi, B Martins, E Smertina… - PLoS …, 2019 - journals.plos.org
Messenger RNA (mRNA) and microRNA (miRNA)-based therapeutics have become
attractive alternatives to DNA-based therapeutics due to recent advances in manufacture …

[HTML][HTML] Nuclear translocation of crk adaptor proteins by the influenza a virus ns1 protein

L Ylösmäki, R Fagerlund, I Kuisma, I Julkunen… - Viruses, 2016 - mdpi.com
The non-structural protein-1 (NS1) of many influenza A strains, especially those of avian
origin, contains an SH3 ligand motif, which binds tightly to the cellular adaptor proteins Crk …